This may result in the activation of several signaling pathways (e.g., MAPK and PI3K/Akt) and transcriptional factors (e.g., NF-κB and HIF-1α), thereby boosting BC progression and therapy resistance [4]. The gene discussed is AKT1; the disease is breast cancer.